OCT 07, 2021 3:00 AM PDT

Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens

WRITTEN BY: Katie Kokolus

Neuroblastoma is a cancer of immature nerve cells found in various areas, including the adrenal glands, neck, chest, or spinal cord. Because these tumors occur in nerve tissue that has not fully developed, this cancer is most common in infants and young children, and about 800 cases are diagnosed annually in the United States.  

A recent study published in Nature Cancer describes a novel immunotherapeutic strategy. The researchers enhanced immune cells so they could effectively seek out and eliminate neuroblastoma cells.  

The novel therapy developed in this study used chimeric antigen receptor T (CAR T) cells. CAR T cells are a type of immunotherapy generated by harvesting a patient’s T cells, the immune cells responsible for attacking and killing tumor cells. The T cells are then modified to recognize specific targets, called antigens, found on the surface of cancer cells. The improved T cells are then reinfused into the patient, where they search for and attack the cancer cells expressing the antigen. 

The CAR T cells used in the study were engineered to target two antigens found on neuroblastoma: GD2 and B7-H3.  In addition, the modified cells also provided stimulation of CD28 and 4-1BB, two vital molecules required for effective anti-tumor immunity.   CD28 is a molecule expressed on T cells and required for T cell activation.  Stimulation of 4-1BB promotes T cell survival and memory functions.

The researchers implanted mice with human neuroblastoma tissue to test the efficacy of their dual targeting CAR T cells.  They found that the CAR T cells eliminated the tumor cells, and the mice treated with these cells achieved long-term survival. In addition, when the treated mice were rechallenged by implantation of more tumor cells, no tumors grew. 

The study results indicate that CAR T cells developed to target two neuroblastoma antigens can identify and kill tumor cells and generate durable memory cells.  These findings suggest that these CAR T cells could be effective in preventing cancer recurrence.

 

Sources: NeuroblastomadiagnosedNature CancerImmunotherapeuticCAR Tantigens

 

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 20, 2021
Drug Discovery & Development
Blood Pressure Drugs Boost Survival in Colorectal Cancer
AUG 20, 2021
Blood Pressure Drugs Boost Survival in Colorectal Cancer
Common drugs used to regulate blood pressure may improve survival rates among patients with colorectal cancer, also know ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
AUG 25, 2021
Chemistry & Physics
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
AUG 25, 2021
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
A new study from the University of Huddersfield shows promising breakthroughs on the use of self-assembling molecules as ...
SEP 02, 2021
Cancer
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
SEP 02, 2021
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
High cholesterol is associated with an increased risk of several types of cancer, and cancer patients with high choleste ...
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
JAN 10, 2022
Cancer
Race May Impact Radiation Efficacy in Prostate Cancer Patients
JAN 10, 2022
Race May Impact Radiation Efficacy in Prostate Cancer Patients
Racial disparities exist between Black and White populations in many types of cancer.  Researchers actively investi ...
Loading Comments...